TWST stock news today

Twist Bioscience criticized in reports by two research outlets

Two research outlets, Hunterbrook and The Bear Cave, released critical reports about Twist Bioscience. The headline does not describe the claims or any reply from the company.

Twist Bioscience shares fall after Bear Cave flags valuation concerns

Twist Bioscience shares dropped after Bear Cave raised concerns about the company's valuation. The report questions whether the stock's price is justified.

Short Seller Publishes Critical Piece on Twist Bioscience

A publication called The Bear Cave released a negative write-up about Twist Bioscience. The headline does not say what the piece claims.

Twist Bioscience faces proposed derivative settlement

A proposed settlement has been noticed in a derivative matter involving Twist Bioscience Corporation. The notice concerns the terms of resolving that case.

Twist Bioscience Offers $1M Legal Fee Deal to End Derivative Suit

The company put forward a plan to resolve a shareholder derivative case, paying $1M in legal fees and adopting changes to how it is governed. The matter would close if the proposal is accepted.

Twist Bioscience shares worth $7.3 million sold by Ark

A fund run by Ark unloaded $7.3 million of Twist Bioscience stock. The move trims the firm's holding in the DNA synthesis business.

Twist Bioscience releases Express Screening Antibodies product

The company rolled out a new antibody tool it calls Express Screening Antibodies. This adds another item to its existing catalog of offerings.

Twist Bioscience debuts MRD Express assay for cancer studies

The company released a new research tool named MRD Express, aimed at cancer studies. It is a product offering for laboratories working in oncology research.

Twist Bioscience debuts new antibody reagent line aimed at scaled output and assays

Twist Bioscience rolled out a new antibody product family designed for large-scale manufacturing and testing workflows. The launch adds to the company's existing antibody offerings.

Twist Bioscience Sets Date for Fiscal 2026 Q4 Earnings Release

The company will publish its fourth-quarter and full-year financial figures for fiscal 2026. The notice gives the timing of its next results update.

Twist Bioscience Backs Contest for Machine-Learning Protein Creation

Twist Bioscience is lending support to a newly launched contest centered on creating proteins with machine-learning methods. The event is run by Poreva.

TD Cowen Keeps Buy Rating on Twist Bioscience, Lifts Target to $190

TD Cowen reiterated its Buy rating on Twist Bioscience and increased its price target to $190. The change reflects the firm's updated view on the stock.

Canaccord Genuity keeps Buy rating on Twist Bioscience, lifts target to $205

Canaccord Genuity reiterated its Buy rating on Twist Bioscience and increased its price target to $205. The update reflects the firm's latest view on the stock.

Jefferies starts Twist Bioscience at Hold, $150 target

Jefferies began covering Twist Bioscience with a Hold rating and set a $150 price target. The stock traded lower following the initiation.

Jefferies starts Twist Bioscience coverage with Hold rating, $150 price target

Jefferies began covering Twist Bioscience with a Hold rating and set a price target of $150. The rating reflects the firm's starting stance on the stock.

Barclays keeps Overweight on Twist Bioscience, lifts target to $215

Barclays reiterated an Overweight rating on Twist Bioscience and raised its price target to $215. The update reflects the firm's latest view on the stock.

Guggenheim raises Twist Bioscience price target to $212 from $107

Guggenheim lifted its price target on Twist Bioscience to $212 from $107. The shares had been up on the news but have since given back that gain.

Guggenheim lifts Twist Bioscience price target to $212 from $107

Guggenheim increased its price target on Twist Bioscience to $212, up from $107. The stock moved higher following the analyst update.

Guggenheim keeps Buy rating on Twist Bioscience, lifts target to $212

Guggenheim reiterated its Buy rating on Twist Bioscience and raised its price target to $212. The update reflects the firm's current view on the stock.

Leerink keeps Outperform on Twist Bioscience, lifts target to $190

Leerink Partners reiterated an Outperform rating on Twist Bioscience and increased its price target to $190 from $160. The stock traded higher following the analyst update.

Leerink Partners keeps Outperform rating on Twist Bioscience, lifts target to $190

Leerink Partners reiterated its Outperform rating on Twist Bioscience and increased its price target to $190. The update reflects the firm's latest view on the company's shares.

Twist Bioscience shares rise on Lilly TuneLab antibody discovery agreement

Twist Bioscience announced a partnership with Lilly TuneLab aimed at advancing antibody drug discovery. The company's stock moved higher following the news.

Twist Bioscience signs agreement with Lilly TuneLab for antibody drug discovery

Twist Bioscience has entered an agreement with Lilly TuneLab aimed at advancing antibody drug discovery. The collaboration focuses on using Twist's technology to support the discovery process.

BWS Financial starts Twist Bioscience coverage with Sell rating, $45 target

BWS Financial began covering Twist Bioscience and assigned a Sell rating. The firm set a price target of $45 for the stock.

UBS starts Twist Bioscience coverage with Neutral rating, $144 price target

UBS began covering Twist Bioscience with a Neutral rating and set a price target of $144. The rating and target reflect the analyst's view of the stock's outlook.

Scorpion Capital Issues Report on Twist Bioscience, Holds Short Position

Scorpion Capital released a report about Twist Bioscience and said it holds a short position in the company. A short position means the firm would benefit if the stock price falls.

What is the latest news on TWST?

Nov 5, 2026: Twist Bioscience criticized in reports by two research outlets (Fiscal.ai) · Nov 5, 2026: Twist Bioscience shares fall after Bear Cave flags valuation concerns (Benzinga) · Nov 5, 2026: Short Seller Publishes Critical Piece on Twist Bioscience (Benzinga)